In the Spotlight

Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients

ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach 

Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance 

In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved. 

In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer 

In recent conflicts, good response to the health needs of refugees with cancer in receiving countries is consequence of an analysis of local cancer centres capacity and special measures to avoid fragmented care  

In his Award Keynote Lecture at the European Lung Cancer Congress 2022, Prof. Fred R. Hirsch describes how ‘the tissue is still the issue’ 

In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry